Indications, technique, and outcome of therapeutic apheresis in European pediatric nephrology units
Indications, technique, and outcome of therapeutic apheresis in European pediatric nephrology units
复制标题
DOI：
10.1007/s00467-014-2907-3
复制
发表时间：
2015-01-01
影响因子：
3
通讯作者：
Edefonti, Alberto
中科院分区：
文献类型：
--
作者：
Paglialonga, Fabio;Schmitt, Claus Peter;Edefonti, Alberto
很少有关于小儿肾脏病学单元格式的观察。这项回顾性研究涉及儿童在121欧洲儿童肾脏肾上腺肾上腺学期间的血浆交换（PE），免疫加载（PE），免疫加载（IA）或双重过滤等离子置换术（IA）或双重过滤等离子置换（DFPP）的儿童零件。 2012年。六十七个儿童接受了PE，十IA和3个DFPP，共有738个PE和349 IA/DFPP会议； 67.2％的PE和69.2％的IA/DFPP患者接受治疗肾脏疾病，特别是局灶性节段性肾小球硬化（FSGS），溶血性尿毒症综合征（HUS）和人类白细胞抗原（HLA），并在进行肾脏之前的肾脏敏感性； 20.9％的PE和23.1％的IA/DFPP患者患有神经系统疾病。膜过滤是最常见的技术，是白蛋白最常用的替代液，肝素是首选的抗凝剂。 PE可在25例患者（37.3％），22例（32.8％）中完全缓解疾病，在20例（29.9％）中无效。七名患者（53.8％），五个（38.5％）的七名患者（53.8％）对IA/DFPP的反应完成，其中1例（7.7％）不存在。在6.9％的PE和9.7％的IA/DFPP Sessions.PE，IA和DFPP的情况下，发生了较小的不良事件。复发性局灶性节段性肾小球硬化病（FSGS），非典型溶血性尿毒症综合征（HUS），人白细胞抗原（HLA）敏感性和神经自身免疫性疾病的儿科患者的功效高。
Few observations on apheresis in pediatric nephrology units have been published.This retrospective study involved children a parts per thousand currency sign18 years undergoing plasma exchange (PE), immunoadsorption (IA), or double filtration plasmapheresis (DFPP) in 12 European pediatric nephrology units during 2012.Sixty-seven children underwent PE, ten IA, and three DFPP, for a total of 738 PE and 349 IA/DFPP sessions; 67.2 % of PE and 69.2 % of IA/DFPP patients were treated for renal diseases, in particular focal segmental glomerulosclerosis (FSGS), hemolytic-uremic syndrome (HUS), and human leukocyte antigen (HLA) desensitization prior to renal transplantation; 20.9 % of PE and 23.1 % of IA/DFPP patients had neurological diseases. Membrane filtration was the most common technique, albumin the most frequently used substitution fluid, and heparin the preferred anticoagulant. PE achieved full disease remission in 25 patients (37.3 %), partial remission in 22 (32.8 %), and had no effect in 20 (29.9 %). The response to IA/DFPP was complete in seven patients (53.8 %), partial in five (38.5 %), and absent in one (7.7 %). Minor adverse events occurred during 6.9 % of PE and 9.7 % of IA/DFPP sessions.PE, IA, and DFPP are safe apheresis methods in children. Efficacy is high in pediatric patients with recurrent focal segmental glomerulosclerosis (FSGS), atypical hemolytic uremic syndrome (HUS), human leukocyte antigen (HLA) sensitization, and neurological autoimmune diseases.